MVZ fuer Haematologie und Onkologie Ravensburg GmbH

The clinical program at MVZ fuer Haematologie und Onkologie Ravensburg focuses on advanced or metastatic non‑small cell lung cancer, a major challenge within the respiratory tract disease spectrum, aiming to extend patient survival through innovative immunotherapy approaches.

• Comparison of overall survival between experimental immunotherapy‑chemo regimen and standard chemotherapy
• Investigation of treatment strategies after resistance to prior checkpoint inhibitors

This work underscores the centre’s dedication to improving outcomes for lung cancer patients in the Ravensburg region.

Research at the site also targets hormone receptor‑positive, HER2‑negative early breast cancer at risk of recurrence, evaluating how education and coaching can sustain adherence to targeted therapy such as ribociclib.

• Assessment of patient education impact on persistence with ribociclib therapy
• Analysis of time to permanent treatment discontinuation as a measure of treatment durability

These studies reflect a patient‑centered approach to breast cancer care, aiming to reduce recurrence through better treatment continuity.